Compare · SENS vs SYK
SENS vs SYK
Side-by-side comparison of Senseonics Holdings Inc. (SENS) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SENS and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $115.59B, about 108.4x SENS ($1.07B).
- Over the past year, SENS is down 32.7% and SYK is down 21.1% - SYK leads by 11.6 points.
- SENS has been more active in the news (23 items in the past 4 weeks vs 8 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 7 for SENS).
- Company
- Senseonics Holdings Inc.
- Stryker Corporation
- Price
- $7.13+6.97%
- $301.60-1.32%
- Market cap
- $1.07B
- $115.59B
- 1M return
- +32.62%
- +2.47%
- 1Y return
- -32.69%
- -21.08%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 23
- 8
- Recent ratings
- 7
- 25
Senseonics Holdings Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest SENS
- Senseonics Holdings Inc. filed SEC Form 8-K: Other Events
- Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems
- SEC Form SD filed by Senseonics Holdings Inc.
- Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026
- Chief Medical Officer Kaufman Francine was granted 63,177 shares, increasing direct ownership by 54% to 181,067 units (SEC Form 4)
- GC & Corp. Development Advisor Horton Kenneth L was granted 157,943 shares, increasing direct ownership by 115% to 295,057 units (SEC Form 4)
- Chief Operating Officer Jain Mukul was granted 270,759 shares, increasing direct ownership by 110% to 517,057 units (SEC Form 4)
- Director Fiorentino Edward was granted 9,852 shares, increasing direct ownership by 13% to 83,339 units (SEC Form 4)
- Director Defalco Stephen P was granted 9,852 shares, increasing direct ownership by 10% to 111,019 units (SEC Form 4)
- Director Roeder Douglas A was granted 9,852 shares, increasing direct ownership by 7% to 154,487 units (SEC Form 4)
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation